Table 3.
Comparison of demographic data between male patients with elevated or normal PRL levels
| Factors | Elevated PRL RIS/OLZ (n=73/n=11) |
Normal PRL RIS/OLZ (n=69/n=55) |
Statistics RIS/OLZ |
P value RIS/OLZ |
| Age, years | 51 (36, 59)/39 (27.25, 52.50) | 42 (29, 56.5)/33 (21.25, 49.75) | U=–1.76/–0.79 | 0.078/0.430 |
| Illness duration, years | 20.89 (10.50, 35)/12 (5.82, 27.88) | 13 (6, 24)/4.58 (1.00, 21.88) | U=–1.85/–1.43 | 0.664/0.152 |
| Age of onset, years | 26 (20, 29)/22.33 (20.52, 28.25) | 25 (20, 30)/23 (19, 30) | U=0.32/–0.29 | 0.747/0.774 |
| Medication time, years | 1.24 (0.10, 2.75)/0.06 (0.003, 1.58) | 0.66 (0.04, 2.13)/0.23 (0.01, 0.73) | U=−1.74/0.35 | 0.082/0.727 |
| Body mass index, kg/m2 | 23.42 (20.76, 25.54)/23.46 (20.57, 26.12) | 23.84 (21.88, 25.49)/22.20 (19.85, 24.08) | U=0.37/1.13 | 0.713/0.199 |
| Dose, mg/day | 4.82 (4, 6)/18.25 (11.25, 20) | 4 (2, 5)/13.52 (10, 20) | U=−2.33/2.52 | 0.020*/0.012* |
| Fasting plasma glucose, mmol/L | 5.01 (4.60, 5.34)/4.60 (4.25, 4.96) | 5.28 (4.84, 5.82)/4.94 (4.44, 5.40) | U=2.62/2.15 | 0.009*/0.03* |
| Total cholesterol, mmol/L | 4.38 (0.97)/4.27 (0.90) | 4.47 (0.91)/4.46 (0.94) | t=–0.58/–0.63 | 0.556/0.529 |
| Triglycerides, mmol/L | 1.27 (0.93, 1.57)/1.43 (0.72, 2.69) | 1.46 (0.99, 1.97)/1.35 (0.91, 1.99) | U=1.79/0.36 | 0.073/0.720 |
| PRL, ng/mL | 47.34 (36.18, 60.59)/42.12 (32.49, 56.13) | 12.70 (2.64, 18.03)/12.55 (2.76, 18.31) | —— | —— |
Normal distribution (mean+SD).
Non-normal distribution (median (Q1, Q3)).
*p≤0.05
OLZ, olanzapine; PRL, prolactin; RIS, risperidone.